Document Detail


Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
MedLine Citation:
PMID:  23196830     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effect of hepatitis C virus (HCV) on antiretroviral therapy (ART) response in patients in sub-Saharan Africa is unknown. We studied 1431 HIV-infected ART initiators in Jos, Nigeria, of whom 6% were HCV coinfected. A similar proportion of HIV/HCV-coinfected and HIV-monoinfected patients achieved HIV RNA <400 copies per milliliter after 24 and 48 weeks of ART (P > 0.05). Hepatotoxicity was uncommon (0.8% and 0.33% at 24 and 48 weeks, respectively) but was more common in the HIV/HCV-coinfected group at 24 (adjusted odds ratio = 19.3; 95% confidence interval: 4.41 to 84.4) and 48 weeks (adjusted odds ratio = 56.7; 95% confidence interval: 5.03 to 636.92). HCV did not significantly impact ART response in this Nigerian cohort.
Authors:
Oche Agbaji; Chloe L Thio; Seema Meloni; Camilla Graham; Mohammed Muazu; Ladep Nimzing; John Idoko; Jean-Louis Sankalé; Ernest Ekong; Robert Murphy; Phyllis Kanki; Claudia Hawkins
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  62     ISSN:  1944-7884     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-18     Completed Date:  2013-03-08     Revised Date:  2014-02-06    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  204-7     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Alanine Transaminase / blood
Anti-Retroviral Agents / adverse effects,  therapeutic use*
Benzoxazines / therapeutic use
Coinfection / blood,  virology*
Deoxycytidine / analogs & derivatives,  therapeutic use
Drug Combinations
Drug Therapy, Combination / adverse effects
Drug-Induced Liver Injury / blood*
Female
HIV Infections / blood,  complications,  drug therapy*
Hepacivirus
Hepatitis C, Chronic / blood,  complications*
Humans
Lamivudine / therapeutic use
Logistic Models
Male
Nevirapine / therapeutic use
Nigeria
Organophosphorus Compounds / therapeutic use
RNA, Viral / blood
Stavudine / therapeutic use
Zidovudine / therapeutic use
Grant Support
ID/Acronym/Agency:
5D43TWOO7995-02//PHS HHS; AACTG.51.PEPFAR.03//PHS HHS; D43 TW007995/TW/FIC NIH HHS; R01 AI071820/AI/NIAID NIH HHS; R01AI071820/AI/NIAID NIH HHS; R56AI060449/AI/NIAID NIH HHS; U01 AI38858/AI/NIAID NIH HHS; U51HA02522//PHS HHS; //PEPFAR
Chemical
Reg. No./Substance:
0/Anti-Retroviral Agents; 0/Benzoxazines; 0/Drug Combinations; 0/Organophosphorus Compounds; 0/RNA, Viral; 0/Truvada; 0W860991D6/Deoxycytidine; 2T8Q726O95/Lamivudine; 4B9XT59T7S/Zidovudine; 99DK7FVK1H/Nevirapine; BO9LE4QFZF/Stavudine; EC 2.6.1.2/Alanine Transaminase; JE6H2O27P8/efavirenz
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Risks and predictors of current suicidality in HIV-infected heroin users in treatment in Yunnan, Chi...
Next Document:  Arabidopsis suppressor mutant of abh1 shows a new face of the already known players: ABH1 (CBP80) an...